AU Stock MarketDetailed Quotes

ATH Alterity Therapeutics Ltd

Watchlist
  • 0.008
  • 0.0000.00%
20min DelayNot Open Apr 28 16:00 AET
71.06MMarket Cap-1.60P/E (Static)

About Alterity Therapeutics Ltd Company

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Company Profile

SymbolATH
Company NameAlterity Therapeutics Ltd
Founded1997
MarketASX
Employees10
Fiscal Year Ends06-30
Address350 Collins Street Level 14
CityMelbourne
CountryAustralia
Zip Code3000
Phone+61 393494906
Share RegistryAUTOMIC REGISTRY SERVICES LEVEL 5, 191 St Georges Terrace,, PERTH, WA, AUSTRALIA, 6000 (08) 9324 2099

Company Executives

  • Name
  • Position
  • Salary
  • Dr. David A. Stamler,M.D.
  • Chief Executive Officer
  • 1.42M
  • Abby Macnish Niven
  • Chief Financial Officer and Company Secretary
  • --
  • Geoffrey Paul Kempler
  • Chairman of the Board
  • 280.00K
  • Lawrence B. Gozlan
  • Director
  • 70.00K
  • Peter A. Marks
  • Independent Director
  • 70.00K
  • Brian Derek Meltzer
  • Independent Director
  • 70.00K

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More